Chronic pain is a vexing worldwide problem that causes substantial disability and consumes
significant medical resources. Although there are numerous analgesic medications, these …

Chronic pain is a widespread healthcare problem affecting not only the patient but in many
ways all the society. Chronic pain is a disease itself that endures for a long period of time …

Background: The current pharmacological treatments for chronic pain are limited. The first
analgesic drug approved for clinical use in decades that has a novel molecular target is the …

The synthetic α-conotoxin Vc1. 1 is a small disulfide bonded peptide currently in
development as a treatment for neuropathic pain. Unlike Vc1. 1, the native post …

The α9α10-nicotinic acetylcholine receptor (nAChR) has been implicated in pain and has
been proposed to be a novel target for analgesics. However, the evidence to support the …

α9α10 nicotinic acetylcholine receptors (nAChRs) have been identified in a variety of tissues
including lymphocytes and dorsal root ganglia; except in the case of the auditory system, the …

Neuropathic pain is a complex and debilitating syndrome for which there are few effective
pharmacological treatments. Opioid‐based medications are initially effective for acute pain …

α-Conotoxin AuIB is a selective α3β4 nicotinic acetylcholine receptor (nAChR) subtype
inhibitor. Its analgesic properties are believed to result from it activating GABA B receptors …

Nicotinic acetylcholine receptors containing α9 subunits are essential for the auditory
function and have been implicated, along with α7-containing nicotinic receptors, as potential …

Neuropathic pain affects millions of people worldwide, causing substantial disability and
greatly impairing quality of life. Commonly used analgesics or antihyperalgesic compounds …